Medicare Enrolled
Dr. Kamel Elzawahry, MD
Neuromusculoskeletal Medicine & OMM Physician · Panama City, FL
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Elzawahry from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Elzawahry?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Elzawahry
Dr. Kamel Elzawahry is a neuromusculoskeletal medicine & omm physician in Panama City, FL, with 20 years of NPI registration. Based on federal Medicare data, Dr. Elzawahry performed 2,743 Medicare services across 1,214 unique beneficiaries.
Between the years covered by Open Payments, Dr. Elzawahry received a total of $6,083 from 57 pharmaceutical and/or device companies across 332 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in neuromusculoskeletal medicine & omm physician. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Elzawahry is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 38% volume in FL
$6,083 industry payments
Medicare Practice Summary
Medicare Utilization ↗2,743
Medicare services
Top 38% in FL for neuromusculoskeletal medicine & omm physician
1,214
Unique beneficiaries
$60
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~137 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,017 | $0 | $15 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
567 | $92 | $260 |
| Facet joint nerve destruction, additional joint This procedure uses imaging guidance to destroy nerves in an additional lower or sacral spinal facet joint. |
159 | $47 | $334 |
| Facet joint nerve destruction, single joint A procedure to destroy nerves in a single lower or sacral spinal facet joint using imaging guidance to target pain signals. |
118 | $152 | $812 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
106 | $132 | $364 |
| Ketorolac injection, per 15 mg An injection of ketorolac tromethamine, a nonsteroidal anti-inflammatory drug, administered in doses measured per 15 mg. |
80 | $0 | $35 |
| Facet joint nerve destruction, additional joint This procedure uses imaging guidance to destroy nerves in an additional upper or middle spinal facet joint. |
78 | $54 | $372 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
78 | $120 | $324 |
| Facet joint nerve destruction, single joint This procedure uses imaging guidance to destroy the nerves supplying a single upper or middle spinal facet joint. It is performed to interrupt pain signals from that specific joint. |
59 | $151 | $828 |
| Spine facet joint injection with imaging guidance, single level An injection is administered into a single facet joint of the lower or sacral spine while using imaging guidance to ensure accurate placement. |
52 | $197 | $904 |
| Facet joint injection, second level, with imaging guidance An injection into a lower or sacral spine facet joint using imaging guidance for the second level treated. |
51 | $106 | $673 |
| Injection of anesthetic or steroid into sacroiliac joint with imaging guidance This procedure involves injecting an anesthetic or steroid medication into the joint connecting the lower spine and hip bone. Imaging guidance is used to ensure accurate placement of the injection. |
41 | $149 | $499 |
| Trigger point injection, 3 or more muscles Injection of medication into three or more specific muscle trigger points to relieve pain. |
35 | $44 | $120 |
| Joint injection, major joint Removal of fluid from a large joint and/or injection of medication into the joint space. |
35 | $47 | $157 |
| Injection of anesthetic or steroid into upper neck and back of head nerve An injection of an anesthetic agent and/or steroid into a nerve located in the upper neck and back of the head. |
34 | $75 | $460 |
| Injection into lower spine canal with imaging guidance A procedure where a substance is injected into the lower part of the spinal canal. The injection is performed using imaging guidance to ensure accurate placement. |
33 | $80 | $600 |
| Trigger point injection, 1-2 muscles A procedure involving the injection of medication into one or two specific muscles to treat trigger points. |
31 | $39 | $110 |
| Sacral spine nerve root injection with imaging guidance An injection of anesthetic and/or steroid medication into a sacral spine nerve root. The procedure uses imaging guidance to ensure accurate placement. |
31 | $89 | $465 |
| Fluoroscopic guidance for needle placement Use of real-time X-ray imaging to guide the precise placement of a needle during a medical procedure. |
30 | $87 | $200 |
| Spine facet joint injection with imaging guidance, single level An injection is administered into a single facet joint of the upper or middle spine while using imaging guidance to ensure accurate placement. |
28 | $206 | $786 |
| Facet joint injection, second level, with imaging An injection into a second spinal facet joint in the upper or middle spine, guided by imaging to ensure accurate placement. |
27 | $115 | $628 |
| Drug test with direct observation A drug screening test performed under direct observation to ensure the sample is provided correctly. This method is used to verify the integrity of the specimen collection process. |
14 | $12 | $40 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
14 | $72 | $185 |
| Additional sacral spine nerve root injection with imaging An injection of anesthetic and/or steroid medication into an additional sacral spine nerve root level, guided by imaging. |
13 | $40 | $400 |
| New patient office visit, complex (60-74 min) | 12 | $177 | $400 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$6,083
Total received (2018-2024)
Avg $869/year across 7 years
Top 16% in FL for neuromusculoskeletal medicine & omm physician
57
Companies
332
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$6,023 (99.0%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$60 (1.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$821
2023
$996
2022
$1,259
2021
$1,303
2020
$553
2019
$620
2018
$531
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$799
ABBVIE INC.
$602
Allergan, Inc.
$304
ACADIA Pharmaceuticals Inc
$260
Teva Pharmaceuticals USA, Inc.
$241
PFIZER INC.
$240
Biogen, Inc.
$231
Alexion Pharmaceuticals, Inc.
$225
AbbVie Inc.
$212
ARGENX US, INC.
$200
Lundbeck LLC
$198
Nevro Corp.
$189
Biohaven Pharmaceuticals, Inc.
$151
Amgen Inc.
$139
IMPEL PHARMACEUTICALS INC.
$128
Greenwich Biosciences, Inc.
$127
JAZZ PHARMACEUTICALS INC.
$123
UCB, Inc.
$113
MDD US Operations, LLC
$98
Octapharma USA, Inc.
$94
US WorldMeds, LLC
$94
Supernus Pharmaceuticals, Inc.
$93
GE HEALTHCARE
$91
Horizon Therapeutics plc
$89
SK Life Science, Inc.
$76
CATALYST PHARMACEUTICALS, INC.
$62
Sunovion Pharmaceuticals Inc.
$51
Merck Sharp & Dohme LLC
$47
Avanir Pharmaceuticals, Inc.
$45
BOSTON SCIENTIFIC CORPORATION
$45
Merck Sharp & Dohme Corporation
$45
EMD Serono, Inc.
$44
MITSUBISHI TANABE PHARMA AMERICA, INC.
$39
Lilly USA, LLC
$39
Allergan Inc.
$39
Bayer HealthCare Pharmaceuticals Inc.
$36
Biohaven Pharmaceutical Holding Company Ltd.
$35
Jazz Pharmaceuticals Inc.
$35
Celgene Corporation
$35
Medtronic, Inc.
$31
ANI Pharmaceuticals, Inc.
$29
CSL Behring
$27
Genentech USA, Inc.
$27
Boston Scientific Corporation
$26
Grifols USA, LLC
$24
SI-BONE, INC.
$23
Acorda Therapeutics, Inc
$20
GRT US Holding, Inc.
$19
Merz Pharmaceuticals, LLC
$19
Eisai Inc.
$18
GENZYME CORPORATION
$18
Merz North America, Inc.
$18
Neos Therapeutics, LP
$18
IDORSIA PHARMACEUTICALS US INC
$17
Promius Pharma LLC
$12
Assertio Therapeutics, Inc.
$12
Abbott Laboratories
$11
Top 3 companies account for 28.0% of total payments
Associated products mentioned in payments ›
ADUHELM · AIMOVIG · AJOVY · APOKYN · APTIOM · AUBAGIO · AUSTEDO · Adzenys XR-ODT · Aimovig · BELSOMRA · BOTOX · BOTOX THERAPEUTIC · COMIRNATY · CUTAQUIG · Cambia · Cenobamate · DUEXIS · EMGALITY · EPIDIOLEX · Epidiolex · FIRDAPSE · FYCOMPA · Fycompa · GENERAL - DBS · GILENYA · GOCOVRI · Gamunex-C · Gocovri · Hizentra · IFUSE IMPLANT · INBRIJA · INTELLIS ADAPTIVESTIM · Infinity DBS Pulse Generators · KESIMPTA · KYNMOBI · Kerendia · LYRICA · MAYZENT · MYOBLOC · NUEDEXTA · NUPLAZID · NURTEC ODT · Nayzilam · Nuedexta · OCREVUS · OCTAGAM IMMUNE GLOBULIN (HUMAN) · ONFI · OXTELLAR XR · PANZYGA · PAXLOVID · PURIFIED CORTROPHIN GEL · QULIPTA · QUVIVIQ · Qutenza · RADICAVA · SOLIRIS · SPECTRA WAVEWRITER · Senza · TECFIDERA · TROKENDI XR · TYSABRI · Trudhesa · UBRELVY · UPLIZNA · VERCISE · VYEPTI · VYVGART · Vimpat · XCOPRI · XEOMIN · XYWAV · Xeomin · Xyrem · ZEPOSIA · Zembrace
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (99%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $222 per 100 Medicare services performed
Geographic Context
Neuromusculoskeletal medicine & omm physicians within 10 mi
3
Per 100K population
1.7
County median income
$70,188
Nearest hospital
HCA FLORIDA GULF COAST HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Elzawahry is a clinical cardiology specialist, with moderate Medicare volume, with low-engagement industry engagement in the top 16% of FL peers, with 20 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Elzawahry experienced with dexamethasone injection (steroid)?
Based on Medicare claims data, Dr. Elzawahry performed 1,017 dexamethasone injection (steroid) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Elzawahry receive payments from pharmaceutical companies?
Yes. Dr. Elzawahry received a total of $6,083 from 57 companies across 332 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Elzawahry's costs compare to other neuromusculoskeletal medicine & omm physicians in Panama City?
Dr. Elzawahry's average Medicare payment per service is $60. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Elzawahry) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Neuromusculoskeletal Medicine & Omm Physicians in Panama City
Browse neuromusculoskeletal medicine & omm physicians in Panama City ranked by procedure volume and transparency data.
Highest volume
Top Neuromusculoskeletal Medicine & Omm Physicians in FL
Neuromusculoskeletal medicine & omm physicians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Neuromusculoskeletal Medicine & Omm Physicians in FL
Which FL neuromusculoskeletal medicine & omm physicians receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
ABBVIE INC. Payments to Doctors
See all physicians who received payments from ABBVIE INC.
By company
Allergan, Inc. Payments to Doctors
See all physicians who received payments from Allergan, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology